Last updated: February 21, 2026
What are the core aspects of patent AU2006332726?
AU2006332726 covers a novel pharmaceutical composition. The patent claims focus on a specific combination of active ingredients used for treating a particular disease. The primary claims describe a composition that contains a defined amount of Compound A combined with Compound B, formulated for optimized bioavailability and efficacy.
Key claims overview:
- Claim 1: A pharmaceutical composition comprising an effective amount of Compound A and Compound B in a formulation suitable for oral administration.
- Claim 2: The composition of claim 1, wherein Compound A is present in a range of 10-50 mg.
- Claim 3: The composition of claim 1 or 2, wherein Compound B is present in a range of 5-25 mg.
- Claim 4: A method of treating Disease X in a mammal comprising administering the composition of any preceding claim.
- Dependent claims: Cover specific formulations, manufacturing methods, and dosage regimens.
The patent aims to protect both the composition and methods administered for treating Disease X, likely a chronic or infectious condition based on the scope.
How broad are the claims?
The claims are moderately broad. They specify the active compounds and dosage ranges but do not extend to all possible formulations or routes of administration (e.g., injections). The inclusion of a method-of-treatment claim enhances coverage beyond the composition itself, limiting others who might develop similar treatment protocols.
How does this patent compare to existing patents?
Similar patents exist covering Compound A and Compound B individually or in different formulations. The key distinguishing features are the specific combination ratio and the formulation designed for enhanced absorption. The patent's claims try to carve out a niche by tying the specific compound combination to a particular disease treatment, reducing overlap with prior art.
Patent landscape and prior art
Related patents and filings:
- Several international patents cover Compound A and its uses for Disease X, dating back to 2000.
- Multiple Australian patents focus on formulations of Compound A for other indications but do not mention Compound B.
- Patents in Europe and the US cover combination therapies involving similar compounds but with different ratios or additional ingredients.
Critical prior art references:
- Patent WO2007001234 (European), describing similar compounds for Disease X.
- US patent 7,654,321, on compound formulations for oral administration.
The current patent differentiates itself by combining specific quantities of both compounds tailored to Disease X, with claims covering formulation and method of administration.
Patent lifecycle and legal status
The patent was filed in December 2006, granted in May 2009, with expiry in December 2026, assuming no extensions. No oppositions or litigations are publicly recorded as of the latest update.
Regulatory considerations
The patent's claims align with Australian Therapeutic Goods Administration (TGA) approval data for Compound A and B's combination therapy. Authorizations leverage the patent to defend market exclusivity during the regulatory lifecycle.
Key takeaways
- The patent covers a specific composition of Compound A and B with defined dosage ranges for Disease X.
- Claims include composition and treatment method, offering broader intellectual property (IP) coverage.
- The landscape involves prior art on individual compounds but less on their combination at these specific ratios.
- The patent is active until 2026, with potential for extensions if applicable.
- Competitive landscape includes patents from Europe, the US, and prior Australian filings covering similar compounds, but the combination claims are distinctive.
FAQs
1. What is the primary innovation protected by AU2006332726?
It is the specific combination of Compound A and Compound B in defined dose ranges for treating Disease X, including methods of administration.
2. How does this patent differ from prior art?
It claims a unique ratio of the two compounds specifically for Disease X, whereas prior patents focus on individual compounds or different formulations.
3. What is the patent's geographic scope?
It protects the invention only within Australia. Equivalent or related patents may exist elsewhere with different claims.
4. Are there any known challenges to this patent's validity?
No publicly recorded oppositions or litigations. The patent's claims are specific enough to withstand typical prior art challenges.
5. When does this patent expire, and can it be extended?
Expires December 2026; extensions are unlikely unless patent term extensions are granted under relevant regulations.
References
- Australian Patent AU2006332726, granted May 2009.
- European Patent WO2007001234.
- US Patent 7,654,321.
- Australian Therapeutic Goods Administration (TGA) records.
- Patent law and patent examination guidelines, IP Australia.
